Ophirex BRAVIO trial misses endpoints but signals krait benefit
Ophirex has published results from its Phase 2 BRAVIO trial evaluating varespladib, a small-molecule inhibitor of snake venom secretory phospholipase A2 (sPLA2), as an adjunct to standard antivenom therapy in snakebite patients across 18 sites in India and the United States. The study, now published in PLOS Neglected Tropical Diseases, enrolled 140 patients bitten by a range of elapids and vipers, including kraits, Russell's vipers, rattlesnakes and copperheads.
The randomised, double-blind, placebo-controlled trial did not meet either of its two prespecified primary endpoints: time to recovery of five-second head-lift in elapid patients, and area under the curve of a composite Snakebite Severity Score in viper patients. The company notes that varespladib was initiated a mean of 7.3 hours after the bite and 3.3 hours after antivenom, a sequencing that is likely to have diluted the measurable effect of sPLA2 inhibition.
Signals in krait and copperhead patients
Despite the primary endpoint misses, Ophirex highlighted subgroup findings the company describes as clinically meaningful. Among krait-bite patients (n=24), those receiving varespladib spent approximately half as much time on mechanical ventilation compared with controls (21 hours versus 40 hours) and showed 36% lower illness severity over the first week. Copperhead patients (n=12) in the varespladib arm experienced a 43% reduction in illness severity across the first two weeks. No serious adverse events were reported in varespladib-treated patients.
Charles Gerardo, co-lead author and professor at Duke University Hospital, acknowledged the timing constraint directly: "Varespladib, as a late adjunctive therapy, was associated with clinically meaningful signals of benefit in krait and copperhead patients. These results are consistent with the known mechanism of action of varespladib and point to the need for further studies."
Regulatory path and the Animal Rule
Ophirex's next development step bypasses a conventional human-efficacy trial. Timothy Platts-Mills, the company's chief medical officer, said the firm is advancing varespladib under the FDA's Animal Rule, a regulatory pathway that permits approval based on adequate and well-controlled animal studies where human efficacy trials are either unethical or not feasible. The Animal Rule has previously supported approvals in fields such as anthrax treatment and nerve-agent antidotes, but its application to snakebite would be relatively novel.
The company intends to publish dedicated subgroup analyses for the krait and copperhead cohorts within the next few months, which may help clarify whether the signals seen are robust enough to underpin an Animal Rule submission.
Market and unmet-need context
Snakebite envenomation kills an estimated 80,000 to 138,000 people annually, with more than 50,000 deaths per year in India alone, according to figures cited in the release drawing on a 2023 Lancet review. The condition is classified as a neglected tropical disease, and antivenom remains the only pharmacologically approved treatment, requiring intravenous administration in a hospital setting. This dependency is a critical structural problem: the majority of deaths occur before patients reach care.
Varespladib's proposed oral formulation is designed specifically to address the prehospital gap, allowing administration at the point of bite. The drug holds FDA Orphan Drug, Paediatric Rare Disease and Fast Track designations, and is supported by the US Defense Health Agency's Small Business Innovation Research programme. Few other small-molecule approaches are at a comparable stage of clinical development for snakebite, though academic groups and organisations such as the Wellcome Trust have funded earlier-stage work on broadly neutralising toxin inhibitors. Ophirex's Public Benefit Corporation structure signals a mission-driven model in a space where commercial returns are constrained by the predominantly low- and middle-income-country disease burden.